Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

Laura X. Wang, Henry T. Quach, Nikil V. Moodabigil, Elizabeth J. Davis, Jeffrey A. Sosman, Stacie B. Dusetzina, Douglas B. Johnson*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Anti–programmed death protein 1 (anti–PD-1) agents have transformed the treatment of advanced melanoma and other cancers, but the rates of steroid-refractory toxicities and health care utilization are not well described. This study assessed these endpoints in patients with melanoma treated with anti–PD-1 with or without ipilimumab. Methods: This study retrospectively evaluated 344 patients with metastatic melanoma treated with anti–PD-1 or a combination of ipilimumab and nivolumab at Vanderbilt University Medical Center from 2009 to 2018. The incidence, types, grades, management, and outcomes of immune-related adverse events (irAEs) and hospitalizations for irAEs and disease progression were assessed. Results: Patients on combination therapy were more likely to develop irAEs than those on monotherapy (72% vs 37%; P <.001) and were more likely to require systemic steroids (61% vs 20%; P <.001), steroid dose re-escalation (23% vs 6%; P <.001), and second-line immunosuppressive use (17% vs 2%; P <.001) and to suffer high-dose steroid–refractory toxicities (23% vs 3%; P <.001). Combination-treated patients were more likely to have any hospitalization (32% vs 7%; P <.001) or multiple hospitalizations for irAEs (11% vs 3%; P =.001) and had a longer average time of hospitalization (mean, 1.92 vs 0.62 days; P =.002). Among 176 hospitalizations related to disease progression in patients who died during evaluable follow-up, 69% occurred within the 90 days before death. Early hospitalizations for disease-related reasons portended a very poor prognosis (median time from admission to death, 58 days). Conclusions: Patients treated with a combination of ipilimumab and nivolumab had higher rates of hospitalization and steroid-refractory toxicities than those treated with anti–PD-1 monotherapy. Disease-associated hospitalizations were similar between the 2 groups, portended a poor prognosis, and mostly occurred in the last months of life.

Original languageEnglish (US)
Pages (from-to)322-328
Number of pages7
JournalCancer
Volume126
Issue number2
DOIs
StatePublished - Jan 15 2020

Keywords

  • death
  • health care utilization
  • immune
  • infliximab
  • ipilimumab
  • nivolumab
  • pembrolizumab
  • steroid
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Wang, L. X., Quach, H. T., Moodabigil, N. V., Davis, E. J., Sosman, J. A., Dusetzina, S. B., & Johnson, D. B. (2020). Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer, 126(2), 322-328. https://doi.org/10.1002/cncr.32542